Autonomix Medical Inc (NASDAQ:AMIX) has been granted a new patent strengthening its neural sensing intellectual property, the company said, adding to a portfolio it ties to what it called the multi-billion-dollar denervation market. Autonomix said the patent grant covers its neural sensing technology and reinforces its intellectual property position.
Autonomix Medical, Inc. (AMIX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Autonomix Medical, Inc. AMIX recently announced that it has been granted a key U.S. patent for its innovative catheter-based platform designed to sense and differentiate nerve signals in real-time. This technology represents a significant leap forward in the field of neuromodulation, with the potential to enhance treatment precision across a wide range of chronic conditions, including cancer and pain management.
Autonomix's RF ablation trial for pancreatic cancer pain shows early success, enabling significant pain relief and opioid elimination in responding patients.
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday.
Autonomix Medical, Inc. AMIX stock is trading higher on Monday, with a strong session volume of 6.11 million compared to the average volume of 22.87 thousand, as per data from Benzinga Pro.
Autonomix Medical (NASDAQ: AMIX ) stock is taking a beating on Tuesday after the development stage medical device company saw its shares undergo a rally yesterday. That came as it provided updates on its pancreatic cancer pain management device.
Medical device firm Autonomix Medical (NASDAQ: AMIX ) popped into traders' radar on Monday, peaking at 150% before engaging in choppy trading. An announcement of a licensing agreement with RF Innovations, a privately held medical technology specialist, catapulted sentiment.